Once-Daily Eslicarbazepine Comparable to Multiple Dosing for Seizure Control

Share this content:
Once-Daily Eslicarbazepine Comparable to Multiple Dosing for Seizure Control
Once-Daily Eslicarbazepine Comparable to Multiple Dosing for Seizure Control

HealthDay News -- Once-daily eslicarbazepine acetate (Aptiom) may control seizures just as well as twice-daily carbamazepine (Tegretol, Carbatrol), according to research scheduled to be presented at the American Academy of Neurology Annual Meeting, held from April 15 to 21 in Vancouver, Canada.

Elinor Ben-Menachem, MD, of Gothenburg University in Sweden, and colleagues compared once-daily eslicarbazepine acetate to twice-daily carbamazepine in 815 patients newly diagnosed with partial seizures.

After 6 months, 71% of those taking eslicarbazepine and 76% of those taking carbamazepine were seizure-free. After 1 year, 65% of those taking eslicarbazepine and 70% of those taking carbamazepine were seizure-free.

"Seizure control is crucial. A once-a-day drug may help people stick to their medication schedule," Dr Ben-Menachem said in a news release from the American Academy of Neurology. "Memory issues, fatigue or a complicated medication schedule can all interfere with a person taking their seizure-control medications on a regular basis," she added, "so having a once-daily option for patients, especially when they are newly diagnosed and still learning to manage the disease, may be beneficial."

The study was funded by Portuguese drug maker BIAL-Portela & Ca.

Go here for more information.

You must be a registered member of Neurology Advisor to post a comment.